Razi Cov Pars

Razi Cov Pars (farsi: رازی کوو پارس ) er en covid-19-vaksinekandidat utviklet av det iranske Razi Vaccine and Serum Research Institute[1][2][3] i Karaj i Iran.

Referanser

  1. ^ «Iran unveils second homegrown COVID-19 vaccine». Anadolu Agency. 7. februar 2021. 
  2. ^ «Phase I, Safety and Immunogenicity of Razi SARS-CoV-2 recombinant Spike protein vaccine (Razi Cov Pars), in healthy adults aged 18-55 years; parallel 4 arms design (adjuvant only and three vaccine doses of 5, 10, and 20 µg/200µl); a Randomised, double blind, clinical trial». irct.ir. Iranian Registry of Clinical Trials. Besøkt 21. mars 2021. 
  3. ^ «Phase II, Safety and Immunogenicity of RAZI SARS-CoV-2 recombinant Spike protein vaccine (RAZI Cov Pars) in adults aged 18-70 years; a Randomised, double blind, parallel 2 arms clinical trial». Iranian Registry of Clinical Trials. Arkivert fra originalen 25. mai 2021. Besøkt 22. april 2021.